Control of Heart Rate in Infant and Child Tachyarrhythmia With Reduced Cardiac Function Using Landiolol (HEARTFUL) - Results of a Prospective, Multicenter, Uncontrolled Clinical Study
BACKGROUND: The prospective Control of HEART rate in inFant and child tachyarrhythmia with reduced cardiac function Using Landiolol (HEARTFUL) study investigated the effectiveness and safety of landiolol, a short-acting β1 selective blocker, in children.Methods and Results: Twenty-five inpatients aged ≥3 months to <15 years who developed supraventricular tachyarrhythmias (atrial fibrillation, atrial flutter, supraventricular tachycardia, and inappropriate sinus tachycardia) were treated with landiolol. The primary endpoint, the percent of patients with a reduction in heart rate ≥20% from the initial rate of tachycardia, or termination of tachycardia at 2 h after starting landiolol, was achieved in 12/25 patients (48.0%; 95% CI 28.4-67.6), which exceeded the predetermined threshold (38.0%). At 2 h after starting landiolol administration, heart rate had decreased by ≥20% in 45.8% (11/24) and recovery to sinus rhythm was achieved in 40.0% (6/15) of the patients. Adverse reactions (ARs) occurred in 24.0% (6/25) of patients, and the study was discontinued in 4.0% (1/25) of the patients; however, none of these ARs were considered serious. The most common AR was hypotension (20.0% [5/25] of patients).
CONCLUSIONS: The HEARTFUL study has demonstrated the efficacy of landiolol, by reducing heart rate or terminating tachycardia, in pediatric patients with supraventricular tachyarrhythmias. Although serious ARs and concerns were not identified in this study, physicians should be always cautious of circulatory collapse due to hypotension.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:87 |
|---|---|
| Enthalten in: |
Circulation journal : official journal of the Japanese Circulation Society - 87(2022), 1 vom: 23. Dez., Seite 130-138 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sagawa, Koichi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
β-blocker |
|---|
| Anmerkungen: |
Date Completed 27.12.2022 Date Revised 06.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1253/circj.CJ-21-0967 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344981789 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344981789 | ||
| 003 | DE-627 | ||
| 005 | 20231226024022.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1253/circj.CJ-21-0967 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM344981789 | ||
| 035 | |a (NLM)35979562 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sagawa, Koichi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Control of Heart Rate in Infant and Child Tachyarrhythmia With Reduced Cardiac Function Using Landiolol (HEARTFUL) - Results of a Prospective, Multicenter, Uncontrolled Clinical Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.12.2022 | ||
| 500 | |a Date Revised 06.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The prospective Control of HEART rate in inFant and child tachyarrhythmia with reduced cardiac function Using Landiolol (HEARTFUL) study investigated the effectiveness and safety of landiolol, a short-acting β1 selective blocker, in children.Methods and Results: Twenty-five inpatients aged ≥3 months to <15 years who developed supraventricular tachyarrhythmias (atrial fibrillation, atrial flutter, supraventricular tachycardia, and inappropriate sinus tachycardia) were treated with landiolol. The primary endpoint, the percent of patients with a reduction in heart rate ≥20% from the initial rate of tachycardia, or termination of tachycardia at 2 h after starting landiolol, was achieved in 12/25 patients (48.0%; 95% CI 28.4-67.6), which exceeded the predetermined threshold (38.0%). At 2 h after starting landiolol administration, heart rate had decreased by ≥20% in 45.8% (11/24) and recovery to sinus rhythm was achieved in 40.0% (6/15) of the patients. Adverse reactions (ARs) occurred in 24.0% (6/25) of patients, and the study was discontinued in 4.0% (1/25) of the patients; however, none of these ARs were considered serious. The most common AR was hypotension (20.0% [5/25] of patients) | ||
| 520 | |a CONCLUSIONS: The HEARTFUL study has demonstrated the efficacy of landiolol, by reducing heart rate or terminating tachycardia, in pediatric patients with supraventricular tachyarrhythmias. Although serious ARs and concerns were not identified in this study, physicians should be always cautious of circulatory collapse due to hypotension | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Landiolol | |
| 650 | 4 | |a Pediatric | |
| 650 | 4 | |a Reduced cardiac function | |
| 650 | 4 | |a Tachyarrhythmia | |
| 650 | 4 | |a β-blocker | |
| 650 | 7 | |a landiolol |2 NLM | |
| 650 | 7 | |a 62NWQ924LH |2 NLM | |
| 650 | 7 | |a Urea |2 NLM | |
| 650 | 7 | |a 8W8T17847W |2 NLM | |
| 650 | 7 | |a Adrenergic beta-Antagonists |2 NLM | |
| 700 | 1 | |a Suzuki, Tsugutoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Takei, Kohta |e verfasserin |4 aut | |
| 700 | 1 | |a Miura, Masaru |e verfasserin |4 aut | |
| 700 | 1 | |a Ueda, Hideaki |e verfasserin |4 aut | |
| 700 | 1 | |a Horigome, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ono, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ohashi, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Seiichi |e verfasserin |4 aut | |
| 700 | 1 | |a Fukunaga, Hideo |e verfasserin |4 aut | |
| 700 | 1 | |a Aoki, Hisaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Miyazaki, Aya |e verfasserin |4 aut | |
| 700 | 1 | |a Sakaguchi, Heima |e verfasserin |4 aut | |
| 700 | 1 | |a Morishima, Eiichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Oki, Kaori |e verfasserin |4 aut | |
| 700 | 1 | |a Sumitomo, Naokata |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation journal : official journal of the Japanese Circulation Society |d 2002 |g 87(2022), 1 vom: 23. Dez., Seite 130-138 |w (DE-627)NLM118044850 |x 1347-4820 |7 nnns |
| 773 | 1 | 8 | |g volume:87 |g year:2022 |g number:1 |g day:23 |g month:12 |g pages:130-138 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1253/circj.CJ-21-0967 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 87 |j 2022 |e 1 |b 23 |c 12 |h 130-138 | ||